Summary :
, which makes a hormone-free contraceptive vaginal gel named Phexxi, have more than doubled since the court ruled that abortion rights are no longer federally protected by the Constitution, leaving it up to Shares of, which makes a hormone-free contraceptive vaginal gel named Phexxi, have more than doubled since the court ruled that abortion rights are no longer federally protected by the Constitution, leaving it up to states to decide whether or not to ban abortions.
Evofem Biosciences had already been preparing for more interest in its products even before the ruling was official. S&P Global Market Intelligence noted in a report last week that Evofem Biosciences is now one of the most heavily shorted stocks in the entire market. Even though Evofem Biosciences shares are still up sharply from their pre- Dobbs v. Jackson Women’s Health Organization ruling levels, the stock has pulled back sharply from its post-decision peak.
<<<<<<<<<<<<<<<<<<<<<
